Page 32 - Yu Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lufax Holding Limited fourth-quarter's 2020 earnings call. [Operator instructions] Please note that this event is being recorded. Now I'd like to hand the conference over to your speaker host today, Mr. Yu Chen, the company's head of board office and capital markets. Please go ahead, sir. Head of Board Office and Capital Markets Thank you, operator. Hello, everyone, and welcome to our fourth-quarter 2020 earnings conference call. Our fourth-quarter 2020 financial and operating results were released by our newswire se...

Auburn fights to the finish line at No. 6 Georgia Tech Story links ATLANTA – Auburn pushed three crucial games to third sets, but the Tigers came just short in a fight to the finish with No. 6 Georgia Tech, falling 5-2 Sunday afternoon. “When you’re climbing a mountain, you can’t always take the same path to the top,” said Auburn head coach Caroline Lilley. “You have to climb in inches and focus on the next step instead of the whole journey ahead. Inch by inch, step by step. Climbing is like a tennis match point by point until the job is done.

Thousand Oaks Biopharmaceutical Group has signed a joint venture agreement with a Korean biotech company in which they will boost serum-free cell culture media production, the companies said on Wednesday. Cell culture media, a liquid or gel designed to support microorganism growth for lab use, will be developed to meet commercial demand on an international scale, according to venture terms. T.O. Bio’s subsidiary, JS Biosciences, will play an integral role in the venture as the current leading cell culture media supplier to China. The deal is with WSG Group, and the venture will focus on bu...

Posted on 7702 January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up and boost development of the Korean Biopharmaceutical industry by supplying serum-free cell culture media at commercial scale. This cooperation also marks another mileston...

Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group By Staff 2 months ago THOUSAND OAKS, Calif. & SHANGHAI & BUSAN, South Korea–(BUSINESS WIRE)–#ASMEBPEcertification–January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up and boost development of the Korean ...